TGFB1 and osteogenesis imperfecta: From a translational perspective, we also conducted a first-in-human phase I study in adults with OI to assess the safety of therapy with fresolimumab, a TGF-β neutralizing antibody, and explored its effects on bone remodeling and bone density.